Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco A Riva

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Rivista Di Psichiatria|May 18, 2021
[Third-generation antipsychotics: focus on cariprazine]Marco A Riva
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|September 19, 2007
CREB, neurogenesis and depressionPeter Gass, Marco A Riva
Pharmaceuticals (Basel, Switzerland)|October 23, 2020
Anti-Stress Properties of Atypical AntipsychoticsAlice Sanson, Marco A Riva
Journal of Reproductive Immunology|May 6, 2014
Prenatal maternal factors in the development of cognitive impairments in the offspringJuliet Richetto, Marco A Riva
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 21, 2023
The complex scenario behind the term antipsychotic drugMarco A Riva, Annamaria Cattaneo
Expert Opinion on Drug Discovery|July 11, 2013
The preclinical profile of lurasidone: clinical relevance for the treatment of schizophreniaFrank I Tarazi, Marco A Riva
Cell and Tissue Research|May 28, 2013
Gene expression profiling as functional readout of rodent models for psychiatric disordersRaffaella Molteni, Flavia Macchi, Marco A Riva
Expert Opinion on Therapeutic Targets|May 12, 2016
Synaptic alterations associated with depression and schizophrenia: potential as a therapeutic targetFrancesca Calabrese, Marco A Riva, Raffaella Molteni
Pharmacology & Therapeutics|June 7, 2011
Antistress properties of antidepressant drugs and their clinical implicationsFrancesca Calabrese, Raffaella Molteni, Marco A Riva
International Clinical Psychopharmacology|December 6, 2007
The interaction between the internal clock and antidepressant efficacyGiorgio Racagni, Marco A Riva, Maurizio Popoli
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Rivista Di Psichiatria|May 18, 2021
[Third-generation antipsychotics: focus on cariprazine]Marco A Riva
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|September 19, 2007
CREB, neurogenesis and depressionPeter Gass, Marco A Riva
Pharmaceuticals (Basel, Switzerland)|October 23, 2020
Anti-Stress Properties of Atypical AntipsychoticsAlice Sanson, Marco A Riva
Journal of Reproductive Immunology|May 6, 2014
Prenatal maternal factors in the development of cognitive impairments in the offspringJuliet Richetto, Marco A Riva
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 21, 2023
The complex scenario behind the term antipsychotic drugMarco A Riva, Annamaria Cattaneo
Expert Opinion on Drug Discovery|July 11, 2013
The preclinical profile of lurasidone: clinical relevance for the treatment of schizophreniaFrank I Tarazi, Marco A Riva
Cell and Tissue Research|May 28, 2013
Gene expression profiling as functional readout of rodent models for psychiatric disordersRaffaella Molteni, Flavia Macchi, Marco A Riva
Expert Opinion on Therapeutic Targets|May 12, 2016
Synaptic alterations associated with depression and schizophrenia: potential as a therapeutic targetFrancesca Calabrese, Marco A Riva, Raffaella Molteni
Pharmacology & Therapeutics|June 7, 2011
Antistress properties of antidepressant drugs and their clinical implicationsFrancesca Calabrese, Raffaella Molteni, Marco A Riva
International Clinical Psychopharmacology|December 6, 2007
The interaction between the internal clock and antidepressant efficacyGiorgio Racagni, Marco A Riva, Maurizio Popoli
Pageof 12